[Application of near infrared spectroscopy in rapid and simultaneous determination of essential components in five varieties of anti-tuberculosis tablets].
Since 1980s, tuberculosis has become increasingly serious. Rifampicin tablets, isoniazide tablets, pyrazinamide tablets, rifampicin and isoniazide tablets and rifampicin isoniazide and pyrazinamide tablets are currently relatively efficacious antituberculosis drugs. In the present paper, near infrared spectroscopy (NIRS) with partial least squares (PLS) was applied to the simultaneous determination of rifampicin (RMP), isoniazide (INH) and pyrazinamide (PZA) contents in 5 varieties of anti-tuberculosis tablets. As the results showed, all of the models for the determination of RMP, INH and PZA contents applied the original NIR spectra. The most efficacious wavelength range for the determination of RMP contents was 1981-2195 nm, it was 1540-1717 nm and 2086-2197 nm for the determination of INH contents, and it was 1460-1537 nm, 1956-2022 nm and 2268-2393 nm for determination of PZA contents. The root mean square error of the calibration set obtained by cross-validation (RMSECV) of the optimum models for the quantitative analysis of RMP, INH and PZA contents was 0.0494, 0.0257 and 0.0307, respectively. Using these optimum models for the determination of RMP, INH and PZA contents in prediction set, the root mean square error of prediction set (RMSEP) was 0.0182, 0.0166 and 0.0134, respectively. The correlation coefficient (r(p)) between the predicted values and actual values was 0.9864, 0.9989 and 0.9993, respectively. These results demonstrated that this method was precise and reliable, and is significative for in situ measurement and the on-line quality control for anti-tuberculosis tablets production.
Teng
Le-sheng
LS
College of Life Science, Jilin University, Changchun 130012, China.
Wang
Di
D
Song
Jia
J
Zhang
Yi-bo
YB
Guo
Wei-liang
WL
Teng
Li-rong
LR
D000465:Algorithms; D000995:Antitubercular Agents / Q000032:analysis* / Q000737:chemistry; D007538:Isoniazid / Q000032:analysis; D008956:Models, Chemical; D025341:Principal Component Analysis; D011718:Pyrazinamide / Q000032:analysis; D012293:Rifampin / Q000032:analysis* / Q000737:chemistry; D019265:Spectroscopy, Near-Infrared / Q000379:methods; D013607:Tablets / Q000032:analysis / Q000737:chemistry
D000995:Antitubercular Agents; D013607:Tablets; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin